These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 12396459)

  • 1. Boosting of SIV-specific T cell responses in rhesus macaques that resist repeated intravaginal challenge with SIVmac251.
    Shacklett BL; Ling B; Veazey RS; Luckay A; Moretto WJ; Wilkens DT; Hu J; Israel ZR; Nixon DF; Marx PA
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1081-8. PubMed ID: 12396459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occult systemic infection and persistent simian immunodeficiency virus (SIV)-specific CD4(+)-T-cell proliferative responses in rhesus macaques that were transiently viremic after intravaginal inoculation of SIV.
    McChesney MB; Collins JR; Lu D; Lu X; Torten J; Ashley RL; Cloyd MW; Miller CJ
    J Virol; 1998 Dec; 72(12):10029-35. PubMed ID: 9811741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated exposure of rhesus macaques to low doses of simian immunodeficiency virus (SIV) did not protect them against the consequences of a high-dose SIV challenge.
    Dittmer U; Stahl-Hennig C; Coulibaly C; Nisslein T; Lüke W; Fuchs D; Bodemer W; Petry H; Hunsmann G
    J Gen Virol; 1995 Jun; 76 ( Pt 6)():1307-15. PubMed ID: 7782761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses.
    Abel K; Compton L; Rourke T; Montefiori D; Lu D; Rothaeusler K; Fritts L; Bost K; Miller CJ
    J Virol; 2003 Mar; 77(5):3099-118. PubMed ID: 12584336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.
    Pal R; Venzon D; Letvin NL; Santra S; Montefiori DC; Miller NR; Tryniszewska E; Lewis MG; VanCott TC; Hirsch V; Woodward R; Gibson A; Grace M; Dobratz E; Markham PD; Hel Z; Nacsa J; Klein M; Tartaglia J; Franchini G
    J Virol; 2002 Jan; 76(1):292-302. PubMed ID: 11739694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251.
    Lü X; Kiyono H; Lu D; Kawabata S; Torten J; Srinivasan S; Dailey PJ; McGhee JR; Lehner T; Miller CJ
    AIDS; 1998 Jan; 12(1):1-10. PubMed ID: 9456249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus.
    Stahl-Hennig C; Voss G; Dittmer U; Coulibaly C; Petry H; Makoschey B; Cranage MP; Aubertin AM; Lüke W; Hunsmann G
    AIDS; 1993 Jun; 7(6):787-95. PubMed ID: 8363756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251.
    Shacklett BL; Shaw KE; Adamson LA; Wilkens DT; Cox CA; Montefiori DC; Gardner MB; Sonigo P; Luciw PA
    J Virol; 2002 Nov; 76(22):11365-78. PubMed ID: 12388697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of human immunodeficiency virus type 2 in macaques after simian immunodeficiency virus SIVmac superinfection.
    Petry H; Dittmer U; Stahl-Hennig C; Coulibaly C; Makoschey B; Fuchs D; Wachter H; Tolle T; Morys-Wortmann C; Kaup FJ
    J Virol; 1995 Mar; 69(3):1564-74. PubMed ID: 7853490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia.
    Miller CJ; Marthas M; Torten J; Alexander NJ; Moore JP; Doncel GF; Hendrickx AG
    J Virol; 1994 Oct; 68(10):6391-400. PubMed ID: 8083977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rhesus macaque resistance to mucosal simian immunodeficiency virus infection is associated with a postentry block in viral replication.
    Peng B; Voltan R; Lim L; Edghill-Smith Y; Phogat S; Dimitrov DS; Arora K; Leno M; Than S; Woodward R; Markham PD; Cranage M; Robert-Guroff M
    J Virol; 2002 Jun; 76(12):6016-26. PubMed ID: 12021334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.
    Kumar A; Mukherjee S; Shen J; Buch S; Li Z; Adany I; Liu Z; Zhuge W; Piatak M; Lifson J; McClure H; Narayan O
    Virology; 2002 Sep; 301(2):189-205. PubMed ID: 12359422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques.
    Ansari AA; Mayne AE; Sundstrom JB; Bostik P; Grimm B; Altman JD; Villinger F
    J Virol; 2002 Feb; 76(4):1731-43. PubMed ID: 11799168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
    Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Th-1-type cytotoxic CD8+ T-lymphocyte responses to simian immunodeficiency virus (SIV) are a consistent feature of natural SIV infection in sooty mangabeys.
    Wang Z; Metcalf B; Ribeiro RM; McClure H; Kaur A
    J Virol; 2006 Mar; 80(6):2771-83. PubMed ID: 16501086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission.
    Putkonen P; Mäkitalo B; Böttiger D; Biberfeld G; Thorstensson R
    J Virol; 1997 Jul; 71(7):4981-4. PubMed ID: 9188561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses.
    Hel Z; Nacsa J; Tryniszewska E; Tsai WP; Parks RW; Montefiori DC; Felber BK; Tartaglia J; Pavlakis GN; Franchini G
    J Immunol; 2002 Nov; 169(9):4778-87. PubMed ID: 12391187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independence of granzyme B secretion and interferon- gamma production during acute simian immunodeficiency virus infection.
    Calarota SA; Otero M; Robinson TM; Dai A; Lewis MG; Boyer JD; Weiner DB
    J Infect Dis; 2006 May; 193(10):1441-50. PubMed ID: 16619193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virus-induced immunosuppression is linked to rapidly fatal disease in infant rhesus macaques infected with simian immunodeficiency virus.
    Otsyula MG; Miller CJ; Marthas ML; Van Rompay KK; Collins JR; Pedersen NC; McChesney MB
    Pediatr Res; 1996 Apr; 39(4 Pt 1):630-5. PubMed ID: 8848337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system.
    Evans DT; Chen LM; Gillis J; Lin KC; Harty B; Mazzara GP; Donis RO; Mansfield KG; Lifson JD; Desrosiers RC; Galán JE; Johnson RP
    J Virol; 2003 Feb; 77(4):2400-9. PubMed ID: 12551977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.